Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…
Filter posts by:
Blog
2025 Oncology Mid-Year Check-in: Reflections & Expectations
Reflecting on the first half of 2025 including data from AACR, ASCO and EHA, we see several notable trends continuing to shape the oncology landscape. While development follows momentum observed the last few years, these learnings provide a clearer understanding into...
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences,...
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated...
Blog
Transforming CRM Data with Precision Technology
Data is the great enabler. It is the backbone of modern Customer Relationship Management (CRM) systems. Data enables businesses to understand their customers better, personalize interactions and make informed decisions. Companies that can harness the power of data have a competitive...
Blog
Operationalizing Generative AI in Life Sciences—Trinity Life Sciences Included in Everest Group Report
The transformative potential of generative AI (GenAI) within the life sciences industry is highlighted in Everest Group’s report, “AI-deas to Action: Operationalizing Generative AI in Life Sciences.” Fifteen companies were selected for inclusion across three categories: To be included in...
Blog
Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which...
